The rhetoric used by critics of the

Piper Jaffray Lowers Price Target On Arena Pharmaceuticals (ARNA) By 6.25

Piper Jaffray told investors in a research report on Monday that it had reduced the price target on Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) from $8 to $7.50. The downward revision is due to a restriction on the price of its Belviq drug for the .

Arena Pharmaceuticals: Belviq In South Korea Keeping Pace With U.S. Launch ...

Disclosure: The author is long ARNA, OREX. (More...)The author wrote this article themselves, and it expresses their own opinions. The author is not receiving compensation for it (other than from Seeking Alpha). The author has no business relationshi